Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02629549 · ClinicalTrials.gov registry record · Phase 1
Intraoperative Imaging of Pituitary Adenomas by OTL
A Phase 1 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT02629549: Clinical Trial Phase 1 study, sponsored by University of Pennsylvania.
NCT02629549 is a Phase 1 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02629549, a Phase 1 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
The primary end-point of the study is to determine the specificity and sensitivity of OTL38 in identifying pituitary adenomas when excited by an imaging probe. The investigators intend to enroll 50 patients in this study. The study is focusing on patients presenting with suspected pituitary adenomas who are considered to be good surgical candidates.
Interventions
- DRUG OTL38
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2015-10 |
| Est. Completion | 2018-08-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02629549
The ClinicalTrials.gov registry entry for NCT02629549 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OTL38 is the first listed.
NCT02629549 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02629549 about?
NCT02629549 is a clinical study titled "Intraoperative Imaging of Pituitary Adenomas by OTL". The primary end-point of the study is to determine the specificity and sensitivity of OTL38 in identifying pituitary adenomas when excited by an imaging probe. The investigators intend to enroll 50 patients in this study. The study is focusing on patients presenting with suspected pituitary adenomas...
What is the current status of trial NCT02629549?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2015-10. Estimated completion is 2018-08-03.
What interventions are being tested in trial NCT02629549?
The interventions under investigation include: OTL38 (DRUG).
Who is sponsoring clinical trial NCT02629549?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.